Xingyiang Biotech and Dongfeng Long Life Sciences Successfully Deliver Custom Glass Bioreactors in Landmark Collaboration

Jun 26, 2024 17:30 CST Updated 17:30

Neukio Biotherapeutics

Developer of Immune Cell Therapeutics

June 24, 2024,Xingyiang (Shanghai) Biotechnology Co., Ltd. and DONGFUJING Life Science in ShanghaiFT-ONE Life Science Industrial ParkHeld the Delivery Ceremony for the First Batch of Customized Glass Bioreactors. This delivery represents the culmination of the preliminary development tailored toPilot Process for the Differentiation and Culture of Induced Pluripotent Stem Cells (iPSC)One result of the cooperation, and a new starting point for in-depth collaboration between the two parties in this field. In the future, both parties will combine their respective advantages to further promote the application of 3D intelligent automation equipment in the standardization and mass production of general-purpose cells, contributing to the development of the industry and the advancement of general cell-based therapeutic drugs.

Xingyiang (Shanghai) Biotechnology Co., Ltd. Chairman Wang Liqun, CMC Vice President Zong Hongliang, Business Development and Strategy Vice President Sun Mu, Dongfeng Life Science City Division General Manager Cheng Jinsheng, Deputy General Manager Nie Liang, and core technical members of both companies conducted in-depth exchanges and discussions on the development trends of the cell and gene therapy (CGT) industry, solutions to industry pain points, integration of resources and advantages, and subsequent cooperation directions. They also jointly participated in the delivery ceremony.

Chairman of Xingyiang (Shanghai) Biotechnology Co., Ltd.—Wang Liqun stated:Xingyiang (Shanghai) Biotechnology Co., Ltd. focuses on iPSC-CAR-NK technology, independently developing a next-generation immunocyte drug technology platform and pipeline that features original innovation, universal off-the-shelf availability, mass production capability, and efficacy in treating solid tumors. Our proprietary closed system for iNK, along with suspension culture, perfusion, feeder-free processes, and pilot-scale production techniques for filling and cryopreservation, represent the most advanced large-scale iPSC-NK cell production process currently available worldwide. However, given that there are no approved products globally yet, automated equipment for scaled production, including bioreactors, also needs to be developed and validated by experienced industrial partners like DONGFENG.

Cheng Jinsheng, General Manager of Dongfu Long Life Science, said:Xingyiang team has extensive experience in the development of universal cell therapy drugs, with a rich innovative pipeline and global strategic positioning. The expertise of DONGFUFU lies in providing process equipment and supporting consumables required in the cell therapy workflow, ensuring convenience and stability of the equipment and consumables. DONGFUFU is highly looking forward to deepening cooperation with Xingyiang, jointly exploring advancements in the cell therapy field, and striving to accelerate the entry of more feasible and accessible cell drugs into the market, contributing to the overall development of the cell drug industry and patient treatment.

With the successful delivery of the glass bioreactor, the collaboration between Xingyiang (Shanghai) Biotechnology Co., Ltd. and DONGFENG Life Science is not only a partnership between two companies but also a commitment to the in-depth exploration of the cell therapy field. We believe that through the joint efforts of both parties, more possibilities can be brought to patient treatment, contributing to the advancement of the cell therapy drug industry.

Xingyiang Biotechnology

Xingyiang (Shanghai) Biotechnology Co., Ltd. focuses on the advanced technology of iPSC-derived CAR-NK, innovating from the two major aspects of product and process development. It develops a new generation of universal, mass-producible immune cell products that can treat solid tumors and autoimmune diseases, filling a global gap. This significantly reduces the production cost of cell products, increases the coverage of indications, and provides accessible and affordable high-quality cell therapies for patients worldwide. The company has obtained 3 national invention patents, with 6 pending national invention patents, 5 PCT applications, and 4 software copyrights. It has completed two rounds of financing totaling $98 million and has now initiated its Series A+ funding round. Within less than three years of its establishment, Xingyiang’s candidate product is about to enter clinical validation.

About SimbayPark

Shanghai FT1 Life Science Park (Abbreviation"Simbay Park, Star North · Free Trade Zone No.1") is located in the Waigaoqiao Bonded Area, the core of Shanghai's Pudong New Area Free Trade Zone. It is an innovative service-oriented characteristic industrial park under the Star North Group, focusing on the incubation, cultivation, and transformation of medical enterprises.The park relies on the unique "Free Trade + Bonded" outward-oriented economic regional advantages. By gathering the entire industry chain service resources of CRO+CDMO+CSO+EHS in biomedicine, government innovation and entrepreneurship support policies, and numerous well-known investment institutions, it provides enterprises with deep technical incubation in the medical industry, becoming a steward for the transformation of corporate technological achievements, and strives to create an international biomedical industry innovation and entrepreneurship base.